β-d-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia

Clinical Microbiology and Infection

Volumn 17, Issue 7, 2011, Pages 1118-1122

  Held, J ^a   Wagner, D ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Follow up; Kinetic; Pneumocystis jirovecii pneumonia; Therapy success; d Glucan

Indexed keywords

ATOVAQUONE; BETA GLUCAN; CLINDAMYCIN; COTRIMOXAZOLE; FOSCARNET SODIUM; GANCICLOVIR; PRIMAQUINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; KINETICS; MEASUREMENT; OUTCOME ASSESSMENT; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE;

PNEUMOCYSTIS JIROVECII;

EID: 79959990489     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03452.x     Document Type: Article

References (11)

1. Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother 2009; 64: 1282-1290.
2. Huang L, Welsh DA, Miller RF et al. Pneumocystis jirovecii dihydropteroate synthase gene mutations and human immunodeficiency virus-associated Pneumocystis pneumonia. J Eukaryot Microbiol 2006; 53: S114-S116.
3. Held J, Koch M, Reischl U, Danner T, Serr A. Serum (1→3)-beta-d-glucan measurement as early indicator for Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect 2010; (in press).
4. Desmet S, Van Wijngaerden E, Maertens J et al. Serum (1-3)-beta-d-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47: 3871-3874.
5. Watanabe T, Yasuoka A, Tanuma J et al. Serum (1→3) beta-d-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009; 49: 1128-1131.
6. Probst M, Ries H, Schmidt-Wieland T, Serr A. Detection of Pneumocystis carinii DNA in patients with chronic lung diseases. Eur J Clin Microbiol Infect Dis 2000; 19: 644-645.
7. Racil Z, Kocmanova I, Lengerova M et al. Difficulties in using 1, 3-{beta}-d-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies-high frequency of false-positive results and their analysis. J Med Microbiol 2010; 59: 1016-1022.
8. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1, 3) {beta}-D glucan test as an aid to the early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010; 48: 4083-4088.
9. Ikemura K, Ikegami K, Shimazu T, Yoshioka T, Sugimoto T. False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J Clin Microbiol 1989; 27: 1965-1968.
10. Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1→3)-beta-d-glucan in blood components and release of (1→3)-beta-d-glucan from depth-type membrane filters for blood processing. Transfusion 2002; 42: 1189-1195.
11. Kanda H, Kubo K, Hamasaki K et al. Influence of various hemodialysis membranes on the plasma (1→3)-β-d-glucan level. Kidney Int 2001; 60: 319-323.